Literature DB >> 9687576

Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine.

A E Busch1, U Karbach, D Miska, V Gorboulev, A Akhoundova, C Volk, P Arndt, J C Ulzheimer, M S Sonders, C Baumann, S Waldegger, F Lang, H Koepsell.   

Abstract

Recently, we cloned the human cation transporter hOCT2, a member of a new family of polyspecific transporters from kidney, and demonstrated electrogenic uptake of tetraethylammonium, choline, N1-methylnicotinamide, and 1-methyl-4-phenylpyridinium. Using polymerase chain reaction amplification, cDNA sequencing, in situ hybridization, and immunohistochemistry, we now show that hOCT2 message and protein are expressed in neurons of the cerebral cortex and in various subcortical nuclei. In Xenopus laevis oocytes expressing hOCT2, electrogenic transport of norepinephrine, histamine, dopamine, serotonin, and the antiparkinsonian drugs memantine and amantadine was demonstrated by tracer influx, tracer efflux, electrical measurements, or a combination. Apparent Km values of 1.9 +/- 0.6 mM (norepinephrine), 1.3 +/- 0.3 mM (histamine), 0.39 +/- 0.16 mM (dopamine), 80 +/- 20 microM (serotonin), 34 +/- 5 microM (memantine), and 27 +/- 3 microM (amantadine) were estimated. Measurement of trans-effects in depolarized oocytes and human embryonic kidney cells expressing hOCT2 suggests that there were different rates and specificities for cation influx and efflux. The hypothesis is raised that hOCT2 plays a physiological role in the central nervous system by regulating interstitial concentrations of monoamine neurotransmitters that have evaded high affinity uptake mechanisms. We show that amantadine does not interact with the expressed human Na+/Cl- dopamine cotransporter. However, concentrations of amantadine that are effective for the treatment of Parkinson's disease may increase the interstitial concentrations of dopamine and other aminergic neurotransmitters by competitive inhibition of hOCT2.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9687576     DOI: 10.1124/mol.54.2.342

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  77 in total

Review 1.  The impact of efflux transporters in the brain on the development of drugs for CNS disorders.

Authors:  Eve M Taylor
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies.

Authors:  Megan Roth; Amanda Obaidat; Bruno Hagenbuch
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 3.  Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems.

Authors:  Akira Tsuji
Journal:  NeuroRx       Date:  2005-01

Review 4.  Regulation of organic cation transport.

Authors:  Giuliano Ciarimboli; Eberhard Schlatter
Journal:  Pflugers Arch       Date:  2004-11-16       Impact factor: 3.657

Review 5.  Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?

Authors:  Lucy Sanchez-Covarrubias; Lauren M Slosky; Brandon J Thompson; Thomas P Davis; Patrick T Ronaldson
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

6.  Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules.

Authors:  Y Urakami; M Okuda; S Masuda; M Akazawa; H Saito; K Inui
Journal:  Pharm Res       Date:  2001-11       Impact factor: 4.200

7.  Characterization of extracellular dopamine clearance in the medial prefrontal cortex: role of monoamine uptake and monoamine oxidase inhibition.

Authors:  H K Wayment; J O Schenk; B A Sorg
Journal:  J Neurosci       Date:  2001-01-01       Impact factor: 6.167

8.  Brain organic cation transporter 2 controls response and vulnerability to stress and GSK3β signaling.

Authors:  T Couroussé; A Bacq; C Belzung; B Guiard; L Balasse; F Louis; A-M Le Guisquet; A M Gardier; A H Schinkel; B Giros; S Gautron
Journal:  Mol Psychiatry       Date:  2014-08-05       Impact factor: 15.992

9.  Quinine enhances the behavioral stimulant effect of cocaine in mice.

Authors:  Adriana Huertas; William D Wessinger; Yuri V Kucheryavykh; Priscila Sanabria; Misty J Eaton; Serguei N Skatchkov; Legier V Rojas; Gerónimo Maldonado-Martínez; Mikhail Y Inyushin
Journal:  Pharmacol Biochem Behav       Date:  2014-12-05       Impact factor: 3.533

10.  Polyamine transport by the polyspecific organic cation transporters OCT1, OCT2, and OCT3.

Authors:  Monica Sala-Rabanal; Dan C Li; Gregory R Dake; Harley T Kurata; Mikhail Inyushin; Serguei N Skatchkov; Colin G Nichols
Journal:  Mol Pharm       Date:  2013-03-19       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.